Healthcare and life sciences

Cirio Advokatbyrå AB

Cirio Advokatbyrå AB houses a broad offering known for its strength in tech-focused life sciences issues, particularly in relation to digital health. Per Hedman leads the ‘very diligent’ team with his deep knowledge of the medtech industry, often assisting with high-value transactional mandates ranging from M&A to licensing and collaboration agreements. Hedman routinely acts for investment entities and both domestic and international biotech and medtech clients. Data protection expert Hanna Tilus is a key contact for all matters concerning tech transfers, major patent litigation, and co-marketing issues. Odd Swarting contributes his longstanding experience in M&A, joint ventures, and financing issues.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

‘The team at Cirio is very diligent and puts a lot of effort into finding solutions fit for purpose. Always reliable.’
‘Hanna Tilus is very diligent and always put a lot of effort into finding solutions that are appropriate for us in a given situation.’
‘Hanna Tilus is a trusted adviser. Honest, pragmatic and business minded.’
‘The team is efficient, delivers hands-on legal advice and are easy-going to work with. I believe the Cirio team has unique strength in the Swedish market thanks to Hanna Tilus, who can combine her expertise within pharmaceuticals and data protection - it is an edge that few other Swedish firms can offer.’

Key clients

Takeda
10x Genomics
Recipharm
Boule Diagnostics
Hadean Ventures
Karolinska Development
Intervacc
Scandinavian Biopharma
Sprint Bioscience
Abliva
Symcel
Annexin Pharmaceuticals
AlzeCure Pharma
Nordberg Medical
Anocca
Lamera Medical
FrostPharma
Lauxera Capital Partners

Work highlights

Advised Abliva on a licensing and collaboration agreement with US-based Owl Therapeutics concerning Abliva’s NeuroSTAT for the treatment of moderate to severe traumatic brain injury.
Advised FrostPharma (controlled by private equity firm Priveq) on its acquisition of Abboxia creating one of the leading specialty pharma companies in the Nordics with a wide product portfolio of hospital pharmaceuticals.
Advised Anocca in relation to its clinical trial of its highly specialised TCR-T cancer therapy 2 involving negotiation of master service agreement with CRO, agreements with other service providers and providing regulatory advice.